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knowledge and skills among RTTs, leading to less ability to 
design, judge or adapt treatment plans. The purpose of this 
work is to show the capabilities of automatic planning and 
discuss its consequence for a radiation-oncology department.  
 
Material and Methods: At the NKI a project was started to 
develop single-click treatment planning for techniques based 
on a class solution. Technically this was accomplished by 
separating medical planning protocol definition from actual 
control of the treatment planning system (Pinnacle3, version 
9.10, Philips Medical Systems). After target delineation, a 
single mouse-click initiates the following actions: Pinnacle 
patient record generation, auto-segmentation of organs at 
risk (OARs), beam setup, optimization of the dose 
distribution, and creation of PDF documentation. The plan is 
then ready for inspection by RTT and physician. This 
procedure is currently implemented into our clinic for 
prostate, breast and vertebral metastases. Currently, 
knowledge and skills among RTTs is primarily maintained by 
the requirement to perform a certain number of treatment 
plans per year for a given tumor site. In addition, all 
treatment plans are checked by a second RTT, and feedback 
is given on deviations from protocol and/or possibilities to 
improve the plan. Finally, special cases are discussed with all 
RTTs on a monthly basis.  
 
Results: A fully automated treatment plan requires 20 
minutes for prostate and breast, and 7 minutes for vertebral 
metastases. Up to now, 185 patients have received a fully 
automated treatment planning procedure. In about 15% of 
the cases, the automatically produced plan required manual 
adjustment, either because of errors in auto-segmentation of 
OARs, or due to a sub-optimal dose distribution. In general, 
RTT hands-on time reduced with up to 2 hours per plan, 
while maintaining plan quality. 
To prevent loss of knowledge and skills among RTTs, 10% of 
the requested plans for a tumor site are randomly assigned 
for manual treatment planning. In addition, planning 
challenges are organized in which a number of RTTs makes a 
treatment plan for the same patient. The results are 
discussed with all RTTs. 
 
Conclusion: Complete automation of the treatment planning 
process is feasible for selected tumor sites and results in 
considerable reduction of hands-on time. By designing new 
QA methods, loss of skills and knowledge among RTTs can be 
prevented, thus ensuring that RTTs remain capable of 
manually designing and/or adapting treatment plans. 
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Purpose or Objective: In definitive radiotherapy for cervical 
cancer, a HDR brachytherapy boost is most commonly used 
after external beam radiation (EBRT). While brachytherapy 
doses are chosen such that a cumulative EqD2 of 80 to 90Gy 
is delivered to the primary tumour after a 45 to 50.4Gy EBRT 
dose, there is less certainty regarding the brachytherapy dose 
contribution to pelvic lymph nodes. This poses a challenge as 
to how high a preceding EBRT dose should be prescribed to 
gross nodal disease, in order to achieve a cumulative 
tumoricidal effect.  
While the use of MRI guided 3-dimensional brachytherapy is 
increasing, the point-based Manchester system remains the 
most widely utilized technique. The objective of this study is 
to determine the brachytherapy dose contribution to 
individual pelvic lymph node regions, using CT planning with 
the Manchester system. 
 
Material and Methods: CT planning datasets from 40 patients 
who had undergone intracavitary HDR brachytherapy for 
stage III or IVA cervical cancer were retrieved. All patients 
received prior 3D conformal EBRT to a dose of 50.4Gy in 28 
fractions, followed by four fractions of CT-based 
brachytherapy, prescribing to Manchester point A. Half of the 
patients (n=20) received a brachytherapy dose of 5Gy per 
fraction, while the other half received 6Gy. Decision on 
brachytherapy dose was dependent on the ability to meet 
D2cc constraints for the adjacent organs-at-risk.  
Following international consensus guidelines, the right and 
left external iliac, internal iliac and obturator groups of 
lymph nodes were separately contoured on the CT dataset 
(see Figure 1). Applying the initial brachytherapy plan on the 
Oncentra TPS, mean doses to each nodal group according to 
laterality (i.e. left and right) were calculated for each 
patient, and both results combined to obtain the average 
mean dose to the entire nodal group. All individual patient 
results were then averaged across the respective study 





Results: A summary of results is shown in Table 1.  
For patients who received a per fraction brachytherapy dose 
of 5 Gy, average mean absolute dose to the external iliac, 
internal iliac, and obturator nodal groups was 0.80 Gy, 1.12 
Gy and 1.34 Gy respectively. The corresponding EQD2s were 
0.72 Gy, 1.05 Gy, and 1.28 Gy respectively.  
For patients who received a per fraction brachytherapy dose 
of 6 Gy, average mean absolute dose to the external iliac, 
internal iliac, and obturator nodal groups was 1.16 Gy, 1.56 
Gy and 1.80 Gy respectively. The corresponding EQD2s were 
1.08 Gy, 1.50 Gy and 1.79 Gy respectively. 
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Conclusion: Our study demonstrates that the pelvic lymph 
nodes receive a significant dose contribution from 
brachytherapy in cervical cancer, when employing the 
Manchester prescription system. This must be taken into 
account during external beam radiotherapy planning, and 
adequate external beam boost doses calculated to achieve 
cumulative tumoricidal doses to pelvic nodal disease.  
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Purpose or Objective: Endometrial cancer is the mainly 
gynaecologic malignancy, 80-85% in stage I at diagnosis. The 
standard primary treatment remains TAH&BSO, with 
appropriate surgical staging. The epidemiology of this disease 
favours elderly, obese women with multiple medical 
problems (hypertension, diabetes, cardiovascular diseases, 
coagulation disorders, respiratory disorders) that render 
some of them medically inoperable. RT alone is the only 
efficient option for these women. BT is the main component 
in this cohort of patients (pts). 
 
Material and Methods: September 1997-September 2015: 90 
pts RT alone, 71 BT HDR alone. Median age 79 years (range 
57-93). Staging: clinical examination, TVUS, MR or CT scan 
and fractionated curettage. Stage Ia 32 pts, Stage Ib 36 pts, 
Stage II 3 pts. OS, DSS, LC and late side effects were analysed 
retrospectively. Follow-up > 10 years (mean 57 months). BT 
HDR with Rotte “Y” applicator, plus VBT in stage II. Dose 
prescription at ‘‘uterine points’’ that are two points located 
1 cm over the middle of a line drawn between the tips of the 
two ends of the "Y" applicator and at series of points placed 
laterally to the tandem according to the pre-treatment 
imaging data. We treat the entire length of the uterus to 
ensure coverage of the fund. To maintain the bladder and 
rectal maximum point doses below 100% of the prescribed 
dose we optimize with TPS. Until 2002 BT was performed 4-5 
times, weekly, mean dose 29.3 Gy (range 18-35 Gy); from 
2003 (42 pts) we deliver 30 Gy in five frs, 6 Gy each b.i.d. 
schedule, 6 hours interval between frs. 
 
Results: 5 years OS, DSS and LC: 52.1%, 85.9%, and 91.2%. 
Stage Ia: 56.3%, 87.5%, and 90.6%; Stage Ib: 50%, 86.1%, 
and 94.4%; Stage II: 33.3%, 66.7%, and 66.7%. DSS was not 
affected by tumour grade or age. One patient had a PD, 6 
(10.6%) developed recurrence after a median of 13 months (3 
with distant metastases), 2 (3.5%) a lymph node recurrence 
with distant metastases. One patient have a GE grade III late 
side effect (1.8%) at 5 years, not related with rectal dose. 
 
Conclusion: HDR BT with “Y” applicator is a very effective 
treatment modality with good LC rates and suitable DSS for 
pts who are not fit for surgery. This technique has proven to 
have a low risk of acute complications and long-term side 
effects. Longer follow-up will be required to document the 
incidence of late effects using the b.i.d. schedule. In the 
short term, it seems that this approach is a feasible way to 
limit the number of procedural complications and length of 
hospital stay and bed rest. 
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Purpose or Objective: Basal cell carcinoma (BCC) is a very 
common cancer in the Caucasian population. Treatment aims 
to eradicate the tumor with the lowest possible functional 
and aesthetic impact. Electronic brachytherapy (EBT) is a 
treatment technique currently emerging. This study aims to 
show the outcomes of two consecutive prospective pilot 
clinical trials using different radiation doses of EBT with 
Esteya® EB system for the treatment of superficial and 
nodular basal cell carcinoma. 
 
Material and Methods: Two prospective, single-center, non-
randomized, pilot studies were conducted. Twenty patients 
were treated in each study with different doses. The first 
group (1) was treated with 36.6 Gy in 6 fractions of 6.1 Gy 
and the second group (2) with 42 Gy in 6 fractions of 7 Gy. In 
one case the 6.1 Gy/fraction resulting from the theorical RBE 
calculation was used, and in the second arm (7 Gy/fraction) 
the same dose as the Valencia applicator study was used. 
Cure rate, acute toxicity and late toxicity related to cosmesis 
were analyzed in the two treatment groups.  
 
Results: In group 1, a complete response in 90% of cases was 
observed at the 1 year follow-up, whereas in group 2 the 
complete response was 95%. Tumor persistence or recurrence 
was suspected clinically and dermoscopically in two patients 
in the first group at 3 and 6 months respectively and in one 
patient in the second group at 1 year follow-up. The 
differences with reference to acute toxicity and the cosmetic 
results between the two treatment groups were not 
statistically significant.  
 
Conclusion: Our initial experience with Esteya® EB system to 
treat superficial and nodular BCC shows that a dose of 36.6 
Gy and 42 Gy delivered in 6 fraction of 7 Gy achieves a 90% 
and 95% clinical cure rate at 1 year respectively. Both groups 
had a tolerable toxicity and a very good cosmesis. 
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Purpose or Objective: Feasibility and dosimetric study of 3D-
printed cylindrical and skin mould applicators for High Dose 
Rate brachytherapy (HDR-BRT) using acrylonitrile butadiene 
styrene (ABS). 
 
Material and Methods: Three cylindrical applicators (1 as 
reference and 2 as test) with a single 2.5 mm catheter 
channel and a 1 mm radial slit for radiochromic film support 
were 3D printed (HP3DX100, Hamlet, Dublin, IE) using ABS 
plastic. The reference had the radiochromic slit in contact 
